Deep Track Capital, LP 13F: Portfolio & Holdings
This page tracks the 13F filings for Deep Track Capital, LP (SEC CIK 0001856083), a GREENWICH-based hedge fund managing $4.80 billion across 62 reported positions as of Q1 2026, per its quarterly SEC Form 13F-HR filing. The Q1 2026 13F filing shows 96.5% of Deep Track's reported portfolio concentrated in Healthcare.
By portfolio weight, the top holdings are GUARDANT HEALTH INC (GH) at 6.36%, IMMUNOVANT, INC. (IMVT) at 5.91%, and TARSUS PHARMACEUTICALS INC (TARS) at 5.21%. Ranked by the share of each peer fund's 13F equity portfolio that overlaps with Deep Track's disclosed positions as of Q1 2026, the closest peers are Jones Hill 13F (50.4%), Paradigm Biocapital Advisors 13F (43.1%), and Exome Asset Management 13F (41.5% overlap).
Most recently, the manager opened a new position in ALUMIS INC. (ALMS) (3.08%), fully exited DYNAVAX TECHNOLOGIES CORP (SYN_268158201) , added to JANUX THERAPEUTICS INC (JANX) (+1225.26% shares), and trimmed CYTOKINETICS INC (CYTK) (-58.82% shares). View the full Q1 2026 allocation shift and trading report →
- 13F AUM
- $4.8B
- Equity Positions
- 62
- Top-10 Concentration
- 44.4%
- Largest Sector · 96.5%
- Healthcare
- Longest-Held Position · 18 qtrs
- IMVT
- Median Holding Period
- 3 Qtrs
Top 10 Holdings — Deep Track — Q1 2026
Largest 13F positions disclosed by Deep Track, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.
| # | Issuer | Ticker | Sector | Weight | Position Value | Detail |
|---|---|---|---|---|---|---|
| 1 | GUARDANT HEALTH INC | GH | Healthcare | 6.36% | $308.4M | Position History All Holders |
| 2 | IMMUNOVANT, INC. | IMVT | Healthcare | 5.91% | $286.3M | Position History All Holders |
| 3 | TARSUS PHARMACEUTICALS INC | TARS | Healthcare | 5.21% | $252.5M | Position History All Holders |
| 4 | VAXCYTE INC | PCVX | Healthcare | 5.16% | $249.9M | Position History All Holders |
| 5 | STRUCTURE THERAPEUTICS INC. | GPCR | Healthcare | 4.26% | $206.3M | Position History All Holders |
| 6 | AXSOME THERAPEUTICS | AXSM | Healthcare | 3.84% | $185.9M | Position History All Holders |
| 7 | APELLIS PHARMACEUTICALS INC | APLS | Healthcare | 3.76% | $182.3M | Position History All Holders |
| 8 | OCULAR THERAPEUTIX INC | OCUL | Healthcare | 3.44% | $166.7M | Position History All Holders |
| 9 | VERA THERAPEUTICS INC | VERA | Healthcare | 3.41% | $165.2M | Position History All Holders |
| 10 | ALUMIS INC. NEW | ALMS | Healthcare | 3.08% | $149.2M | Position History All Holders |
View Deep Track's Q1 2026 allocation shift and trading report →
Portfolio composition
Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.
Quarterly shiftsQ1 2026 vs previous quarter
Top movers in Deep Track's Form 13F versus the prior reporting quarter. Δ Weight is the change in portfolio weight (percentage points); Δ Shares is the percent change in share count.
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| JANUX THERAPEUTICS INC | JANX | +0.31% | +1225.26% |
| INVENTIVA SA | IVA | +0.09% | +149.48% |
| OCULAR THERAPEUTIX INC | OCUL | +1.21% | +143.93% |
| COGENT BIOSCIENCES INC | COGT | +0.43% | +120.70% |
| ALKERMES PLC | ALKS | +1.34% | +79.52% |
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| CYTOKINETICS INC | CYTK | -2.97% | -58.82% |
| BIOMARIN PHARMACEUTICALS | BMRN | -1.78% | -50.00% |
| VIRIDIAN THERAPEUTICS, INC. | VRDN | -1.23% | -44.79% |
| APELLIS PHARMACEUTICALS INC | APLS | -0.68% | -41.52% |
| CELLDEX THERAPEUTICS INC | CLDX | -0.34% | -32.45% |
| Company | Ticker | New weight |
|---|---|---|
| ALUMIS INC.NEW | ALMS | 3.08% |
| NUVALENT INCNEW | NUVL | 2.91% |
| GENMAB A/SNEW | GMAB | 2.03% |
| DEFINIUM THERAPEUTICS INCNEW | DFTX | 1.17% |
| ATAIBECKLEY INCNEW | ATAI | 0.88% |
| Company | Ticker | Prev weight |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORP | SYN_268158201 | 5.52% |
| MIND MEDICINE MINDMED INC | SYN_60255C885 | 0.51% |
| ATAI BECKLEY NV | SYN_N0731H103 | 0.44% |
| XENON PHARMACEUTICALS INC | XENE | 0.37% |
| MONOPAR THERAPEUTICS INC | MNPR | 0.14% |
Waterfall analysis
Top movers versus the prior reporting quarter. Left panel bridges market-value change in USD millions; right panel shows share-count change in %.
Holding period analytics
Distribution of holding periods for all 221 stocks the fund has ever held (up to selected quarter):
Which Funds Hold a Similar Portfolio to Deep Track?
Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Deep Track's positions in Q1 2026.
| # | Fund | Shared Positions | Overlap % |
|---|---|---|---|
| 1 | Jones Hill 13F | 9 | 50.4% |
| 2 | Paradigm Biocapital Advisors 13F | 15 | 43.1% |
| 3 | Exome Asset Management 13F | 14 | 41.5% |
| 4 | Commodore Capital 13F | 11 | 36.9% |
| 5 | Deerfield 13F | 10 | 33.2% |
How Has Deep Track's AUM Changed Over Time?
Quarterly 13F-reported AUM for Deep Track, derived from aggregate reported position market values disclosed to the U.S. SEC.
| Quarter | 13F AUM (USD) | QoQ Change |
|---|---|---|
| Q4 2021 | $1.4B | — |
| Q1 2022 | $1.5B | +0.20B |
| Q2 2022 | $1.4B | -0.10B |
| Q3 2022 | $2.0B | +0.58B |
| Q4 2022 | $2.3B | +0.27B |
| Q1 2023 | $2.4B | +0.06B |
| Q2 2023 | $2.1B | -0.21B |
| Q3 2023 | $2.6B | +0.44B |
| Q4 2023 | $2.9B | +0.28B |
| Q1 2024 | $3.5B | +0.62B |
| Q2 2024 | $3.3B | -0.13B |
| Q3 2024 | $3.1B | -0.22B |
| Q4 2024 | $2.7B | -0.47B |
| Q1 2025 | $3.1B | +0.42B |
| Q2 2025 | $3.1B | +0.02B |
| Q3 2025 | $3.6B | +0.47B |
| Q4 2025 | $4.4B | +0.80B |
| Q1 2026 | $4.8B | +0.46B |
Methodology & FAQ
How We Track Deep Track Holdings
Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).
- Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
- What is Included (Data Scope): By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
- Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
- How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Deep Track's 13F filing disclose about their portfolio?
A Form 13F-HR filed by Deep Track with the U.S. SEC discloses all long positions in Section 13(f) securities — U.S.-listed equities, ETFs, closed-end funds, and listed put/call options — held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface Deep Track’s reported portfolio weights, share counts, and quarter-over-quarter allocation shifts in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.
How do you measure conviction in Deep Track's portfolio allocations?
Conviction is measured by portfolio weight — the percentage of Deep Track’s total reported 13F market value allocated to a given position — rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings. Tracking how that weight changes quarter-over-quarter separates active reallocation decisions from passive price appreciation drift.
What is excluded from Deep Track's 13F — short positions, swaps, and derivatives?
SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives — none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Deep Track’s 13F represents the reported long book, which may differ materially from its net economic exposure.
When is Deep Track's 13F data available, and how large is the reporting lag?
Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published — managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Deep Track. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.
Who must file a Form 13F with the SEC, and does Deep Track qualify?
Under SEC Rule 13f-1, any investment manager — including hedge funds, family offices, registered investment advisers, pension funds, and university endowments — that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Deep Track meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.